Association of Body Composition with Long-Term Survival inNon-metastatic Rectal Cancer Patients
- Author:
Jin Soo HAN
1
;
Hyoseon RYU
;
In Ja PARK
;
Kyung Won KIM
;
Yongbin SHIN
;
Sun Ok KIM
;
Seok-Byung LIM
;
Chan Wook KIM
;
Yong Sik YOON
;
Jong Lyul LEE
;
Chang Sik YU
;
Jin Cheon KIM
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2020;52(2):563-572
- CountryRepublic of Korea
- Language:0
-
Abstract:
Purpose:We evaluated the association of body composition with long-term oncologic outcomes innon-metastatic rectal cancer patients.
Materials and Methods:We included 1,384 patients with stage(y)0-III rectal cancer treated at Asan Medical Centerbetween January 2005 and December 2012. Body composition at diagnosis was measuredusing abdomino-pelvic computed tomography (CT). Sarcopenia, visceral obesity (VO), andsarcopenic obesity (SO) were defined using CT measured parameters such as skeletal muscleindex (total abdominal muscle area, TAMA), visceral fat area (VFA), and VFA/TAMA. Inflammatorystatus was defined as a neutrophil-lymphocyte ratio of ! 3. Obesity was categorizedby body mass index (! 25 kg/m2).
Results:Among the 1,384 patients, 944 (68.2%) had sarcopenia and 307 (22.2%) had SO. The5-year overall survival (OS) rate was significantly lower in sarcopenic patients (no sarcopeniavs. sarcopenia; 84% vs. 78%, p=0.003) but the 5-year recurrence-free survival (RFS) ratewas not different (77.3% vs. 77.9% p=0.957). Patients with SO showed lower 5-year OS(79.1% vs. 75.5% p=0.02) but no difference in 5-year RFS (p=0.957). Sarcopenia, SO, VO,and obesity were not associated with RFS. However, obesity, SO, age, sex, inflammatorystatus, and tumor stage were confirmed as independent factors associated with OS on multivariateanalysis. In subgroup analysis, association of SO with OS was more prominent inpatients with (y)p stage 0-2 and no inflammatory status.
Conclusion:The presence of SO and a low body mass index at diagnosis are negatively associated withOS in non-metastatic rectal cancer patients.
